Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities.

The discovery of the genetic causes of syndromic autism spectrum disorders and intellectual disabilities has greatly informed our understanding of the molecular pathways critical for normal synaptic function. The top-down approaches using human phenotypes and genetics helped identify causative genes and uncovered the broad spectrum of neuropsychiatric features that can result from various mutations in the same gene. Importantly, the human studies unveiled the exquisite sensitivity of cognitive function to precise levels of many diverse proteins. Bottom-up approaches applying molecular, biochemical, and neurophysiological studies to genetic models of these disorders revealed unsuspected pathogenic mechanisms and identified potential therapeutic targets. Moreover, studies in model organisms showed that symptoms of these devastating disorders can be reversed, which brings hope that affected individuals might benefit from interventions even after symptoms set in. Scientists predict that insights gained from studying these rare syndromic disorders will have an impact on the more common nonsyndromic autism and mild cognitive deficits.

[1]  Y. Zhang,et al.  The Angelman syndrome protein Ube3a regulates synapse development by ubiquitinating Tkv in Drosophila , 2013 .

[2]  J. Christodoulou,et al.  MECP2-Related Disorders , 2012 .

[3]  H. Van Esch MECP2 Duplication Syndrome , 2011, Molecular Syndromology.

[4]  M. Sahin,et al.  TSC1/TSC2 signaling in the CNS , 2011, FEBS letters.

[5]  M. Sahin,et al.  Mechanisms of neurocognitive dysfunction and therapeutic considerations in tuberous sclerosis complex. , 2011, Current opinion in neurology.

[6]  C. Betancur,et al.  Etiological heterogeneity in autism spectrum disorders: More than 100 genetic and genomic disorders and still counting , 2011, Brain Research.

[7]  Laurent Mottron,et al.  Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia , 2011, Human Genetics.

[8]  E. Thiele,et al.  Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex , 2011, Neurology.

[9]  M. Giustetto,et al.  Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. , 2011, Human molecular genetics.

[10]  G. Feng,et al.  Shank3 mutant mice display autistic-like behaviours and striatal dysfunction , 2011, Nature.

[11]  M. Bear,et al.  New views of Arc, a master regulator of synaptic plasticity , 2011, Nature Neuroscience.

[12]  A. Jauch,et al.  De novo MECP2 duplication in two females with random X-inactivation and moderate mental retardation , 2011, European Journal of Human Genetics.

[13]  J. Hablitz,et al.  Network hyperexcitability in hippocampal slices from Mecp2 mutant mice revealed by voltage-sensitive dye imaging. , 2011, Journal of neurophysiology.

[14]  Alcino J. Silva,et al.  Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders. , 2011, Trends in molecular medicine.

[15]  Mark F Bear,et al.  Toward fulfilling the promise of molecular medicine in fragile X syndrome. , 2011, Annual review of medicine.

[16]  Janice Branson,et al.  Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056 , 2011, Science Translational Medicine.

[17]  P. D. Vries,et al.  Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex , 2010, Neurotherapeutics.

[18]  R. Hagerman,et al.  Fragile X: Leading the way for targeted treatments in autism , 2010, Neurotherapeutics.

[19]  Mark J. Harris,et al.  Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication , 2010, Molecular autism.

[20]  B. Philpot,et al.  Angelman syndrome: advancing the research frontier of neurodevelopmental disorders , 2010, Journal of Neurodevelopmental Disorders.

[21]  W. Kaufmann,et al.  Rett syndrome: Revised diagnostic criteria and nomenclature , 2010, Annals of neurology.

[22]  M. Bear,et al.  Hypersensitivity to mGluR5 and ERK1/2 Leads to Excessive Protein Synthesis in the Hippocampus of a Mouse Model of Fragile X Syndrome , 2010, The Journal of Neuroscience.

[23]  Fred H. Gage,et al.  A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem Cells , 2010, Cell.

[24]  Rodney C. Samaco,et al.  GABAergic dysfunction mediates autism-like stereotypies and Rett syndrome phenotypes , 2010, Nature.

[25]  B. Oostra,et al.  Potential therapeutic interventions for fragile X syndrome. , 2010, Trends in molecular medicine.

[26]  T. Jongens,et al.  Fragile X syndrome and model organisms: identifying potential routes of therapeutic intervention , 2010, Disease Models & Mechanisms.

[27]  Mika Nakamoto,et al.  Excess Phosphoinositide 3-Kinase Subunit Synthesis and Activity as a Novel Therapeutic Target in Fragile X Syndrome , 2010, The Journal of Neuroscience.

[28]  Tatiana Nikitina,et al.  MeCP2 Binds Cooperatively to Its Substrate and Competes with Histone H1 for Chromatin Binding Sites , 2010, Molecular and Cellular Biology.

[29]  W. Kaufmann,et al.  Defective GABAergic Neurotransmission and Pharmacological Rescue of Neuronal Hyperexcitability in the Amygdala in a Mouse Model of Fragile X Syndrome , 2010, The Journal of Neuroscience.

[30]  J. Arunachalam,et al.  MeCP2270 Mutant Protein Is Expressed in Astrocytes as well as in Neurons and Localizes in the Nucleus , 2010, Cytogenetic and Genome Research.

[31]  Allen D. Delaney,et al.  Conserved Role of Intragenic DNA Methylation in Regulating Alternative Promoters , 2010, Nature.

[32]  Ute Moog,et al.  Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation , 2010, Nature Genetics.

[33]  D. Kunze,et al.  Exogenous Brain-Derived Neurotrophic Factor Rescues Synaptic Dysfunction in Mecp2-Null Mice , 2010, The Journal of Neuroscience.

[34]  Izumi Maezawa,et al.  Rett Syndrome Microglia Damage Dendrites and Synapses by the Elevated Release of Glutamate , 2010, The Journal of Neuroscience.

[35]  Marie-Pierre Dubé,et al.  De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia , 2010, Proceedings of the National Academy of Sciences.

[36]  Yiping Shen,et al.  Deletions of NRXN1 (Neurexin-1) Predispose to a Wide Spectrum of Developmental Disorders , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[37]  M. Sur,et al.  Loss of Arc renders the visual cortex impervious to the effects of sensory experience or deprivation , 2010, Nature Neuroscience.

[38]  M. Stryker,et al.  Genomic imprinting of experience-dependent cortical plasticity by the ubiquitin ligase gene Ube3a , 2010, Proceedings of the National Academy of Sciences.

[39]  Z. Ou,et al.  Deletion Syndrome : Clinical and Molecular Analysis Using Array CGH , 2010 .

[40]  Alan R. Mardinly,et al.  The Angelman Syndrome Protein Ube3A Regulates Synapse Development by Ubiquitinating Arc , 2010, Cell.

[41]  Robert S. Illingworth,et al.  Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. , 2010, Molecular cell.

[42]  P. Stankiewicz,et al.  Structural variation in the human genome and its role in disease. , 2010, Annual review of medicine.

[43]  Mustafa Sahin,et al.  Tsc2-Rheb Signaling Regulates EphA-Mediated Axon Guidance , 2009, Nature Neuroscience.

[44]  O. Paulsen,et al.  The roles of GABAB receptors in cortical network activity. , 2010, Advances in pharmacology.

[45]  P. D. de Vries Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex. , 2010, Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.

[46]  Rodney C. Samaco,et al.  Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities , 2009, Proceedings of the National Academy of Sciences.

[47]  J. Lupski,et al.  Autism and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndrome , 2009, Annals of neurology.

[48]  C. Barthélémy,et al.  Autism and Nonsyndromic Mental Retardation Associated with a De Novo Mutation in the NLGN4X Gene Promoter Causing an Increased Expression Level , 2009, Biological Psychiatry.

[49]  Annette Schenck,et al.  CNTNAP2 and NRXN1 are mutated in autosomal-recessive Pitt-Hopkins-like mental retardation and determine the level of a common synaptic protein in Drosophila. , 2009, American journal of human genetics.

[50]  J. LaSalle,et al.  Evolving role of MeCP2 in Rett syndrome and autism. , 2009, Epigenomics.

[51]  S. Auvin,et al.  MEF2C haploinsufficiency caused by either microdeletion of the 5q14.3 region or mutation is responsible for severe mental retardation with stereotypic movements, epilepsy and/or cerebral malformations , 2009, Journal of Medical Genetics.

[52]  David R. Hampson,et al.  Increased GABAB Receptor-Mediated Signaling Reduces the Susceptibility of Fragile X Knockout Mice to Audiogenic Seizures , 2009, Molecular Pharmacology.

[53]  R. Prakash,et al.  Ube3a is required for experience-dependent maturation of the neocortex , 2009, Nature Neuroscience.

[54]  J. Frahm,et al.  Neuroligin‐3‐deficient mice: model of a monogenic heritable form of autism with an olfactory deficit , 2009, Genes, brain, and behavior.

[55]  E. Masliah,et al.  Widespread changes in dendritic and axonal morphology in Mecp2‐mutant mouse models of rett syndrome: Evidence for disruption of neuronal networks , 2009, The Journal of comparative neurology.

[56]  D. Harvey,et al.  Rett Syndrome Astrocytes Are Abnormal and Spread MeCP2 Deficiency through Gap Junctions , 2009, The Journal of Neuroscience.

[57]  H. Covington,et al.  MeCP2-Mediated Transcription Repression in the Basolateral Amygdala May Underlie Heightened Anxiety in a Mouse Model of Rett Syndrome , 2009, The Journal of Neuroscience.

[58]  R. Jaenisch,et al.  Phosphorylation of MeCP2 at Serine 80 regulates its chromatin association and neurological function , 2009, Proceedings of the National Academy of Sciences.

[59]  G. Mandel,et al.  Non–cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology , 2009, Nature Neuroscience.

[60]  Elvira Bramon,et al.  Disruption of the neurexin 1 gene is associated with schizophrenia. , 2009, Human molecular genetics.

[61]  Wei Zhang,et al.  Pharmacological Inhibition of mTORC1 Suppresses Anatomical, Cellular, and Behavioral Abnormalities in Neural-Specific Pten Knock-Out Mice , 2009, The Journal of Neuroscience.

[62]  Nathan R. Wilson,et al.  Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice , 2009, Proceedings of the National Academy of Sciences.

[63]  Michael P. Stryker,et al.  Reversing Neurodevelopmental Disorders in Adults , 2008, Neuron.

[64]  Mark F. Bear,et al.  The Autistic Neuron: Troubled Translation? , 2008, Cell.

[65]  T. Südhof Neuroligins and neurexins link synaptic function to cognitive disease , 2008, Nature.

[66]  Michelle N. Ngo,et al.  Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model , 2008, Journal of Medical Genetics.

[67]  Huda Y. Zoghbi,et al.  Deletion of Mecp2 in Sim1-Expressing Neurons Reveals a Critical Role for MeCP2 in Feeding Behavior, Aggression, and the Response to Stress , 2008, Neuron.

[68]  Alcino J. Silva,et al.  Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis , 2008, Nature Medicine.

[69]  Ravinesh A. Kumar,et al.  Novel Submicroscopic Chromosomal Abnormalities Detected in Autism Spectrum Disorder , 2008, Biological Psychiatry.

[70]  Stephen T. C. Wong,et al.  MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription , 2008, Science.

[71]  M. C. Phelan Orphanet Journal of Rare Diseases BioMed Central Review Deletion 22q13.3 syndrome , 2008 .

[72]  Mustafa Sahin,et al.  Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function , 2008, The Journal of Neuroscience.

[73]  S. Sommer,et al.  Familial deletion within NLGN4 associated with autism and Tourette syndrome , 2008, European Journal of Human Genetics.

[74]  D. Geschwind,et al.  Advances in autism genetics: on the threshold of a new neurobiology , 2008, Nature Reviews Genetics.

[75]  H. Zoghbi,et al.  Specific mutations in Methyl-CpG-Binding Protein 2 confer different severity in Rett syndrome , 2008, Neurology.

[76]  A. Sawa,et al.  [Neurodevelopmental disturbance in the pathogenesis of major mental disorders]. , 2008, Brain and nerve = Shinkei kenkyu no shinpo.

[77]  Daniela C. Zarnescu,et al.  Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. , 2008, Nature chemical biology.

[78]  Liang Zhang,et al.  The MeCP2‐null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability , 2008, Hippocampus.

[79]  Mark F Bear,et al.  Smaller Dendritic Spines, Weaker Synaptic Transmission, but Enhanced Spatial Learning in Mice Lacking Shank1 , 2008, The Journal of Neuroscience.

[80]  Jens Frahm,et al.  Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism , 2008, Proceedings of the National Academy of Sciences.

[81]  Yiping Shen,et al.  Disruption of neurexin 1 associated with autism spectrum disorder. , 2008, American journal of human genetics.

[82]  M. Missler,et al.  Early defects of GABAergic synapses in the brain stem of a MeCP2 mouse model of Rett syndrome. , 2008, Journal of neurophysiology.

[83]  Mark F. Bear,et al.  Correction of Fragile X Syndrome in Mice , 2007, Neuron.

[84]  J M Friedman,et al.  A patient with vertebral, cognitive and behavioural abnormalities and a de novo deletion of NRXN1α , 2007, Journal of Medical Genetics.

[85]  M. Bieda,et al.  Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes , 2007, Proceedings of the National Academy of Sciences.

[86]  Christian R Marshall,et al.  Contribution of SHANK3 mutations to autism spectrum disorder. , 2007, American journal of human genetics.

[87]  J. Inazawa,et al.  22q13 microduplication in two patients with common clinical manifestations: A recognizable syndrome? , 2007, American journal of medical genetics. Part A.

[88]  J. Cheadle,et al.  Cognitive deficits in Tsc1+/−mice in the absence of cerebral lesions and seizures , 2007, Annals of neurology.

[89]  Huda Y. Zoghbi,et al.  The Story of Rett Syndrome: From Clinic to Neurobiology , 2007, Neuron.

[90]  Jacqueline Blundell,et al.  A Neuroligin-3 Mutation Implicated in Autism Increases Inhibitory Synaptic Transmission in Mice , 2007, Science.

[91]  Christian Rosenmund,et al.  MeCP2 Controls Excitatory Synaptic Strength by Regulating Glutamatergic Synapse Number , 2007, Neuron.

[92]  H. Zoghbi,et al.  Trinucleotide repeat disorders. , 2007, Annual review of neuroscience.

[93]  T. Südhof,et al.  Activity-Dependent Validation of Excitatory versus Inhibitory Synapses by Neuroligin-1 versus Neuroligin-2 , 2007, Neuron.

[94]  U. Francke,et al.  Cerebellar gene expression profiles of mouse models for Rett syndrome reveal novel MeCP2 targets , 2007, BMC Medical Genetics.

[95]  A. Bird,et al.  Reversal of Neurological Defects in a Mouse Model of Rett Syndrome , 2007, Science.

[96]  R. Jaenisch,et al.  Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2 , 2007, Proceedings of the National Academy of Sciences.

[97]  M. Bear,et al.  Activity-dependent regulation of NR2B translation contributes to metaplasticity in mouse visual cortex , 2007, Neuropharmacology.

[98]  Thomas Bourgeron,et al.  Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders , 2007, Nature Genetics.

[99]  E. Weeber,et al.  Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of αCaMKII inhibitory phosphorylation , 2007, Nature Neuroscience.

[100]  Ankita Patel,et al.  Increased MECP2 gene copy number as the result of genomic duplication in neurodevelopmentally delayed males , 2006, Genetics in Medicine.

[101]  Eric C. Griffith,et al.  Brain-Specific Phosphorylation of MeCP2 Regulates Activity-Dependent Bdnf Transcription, Dendritic Growth, and Spine Maturation , 2006, Neuron.

[102]  Thomas C. Südhof,et al.  Neuroligins Determine Synapse Maturation and Function , 2006, Neuron.

[103]  G. Baird,et al.  Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP) , 2006, The Lancet.

[104]  P. Huppke,et al.  Very mild cases of Rett syndrome with skewed X inactivation , 2006, Journal of Medical Genetics.

[105]  Amy Brand,et al.  CROSSREF , 2006 .

[106]  P. Tam,et al.  Mecp2 deficiency is associated with learning and cognitive deficits and altered gene activity in the hippocampal region of mice. , 2006, Brain : a journal of neurology.

[107]  R. Jaenisch,et al.  Postnatal Loss of Methyl-CpG Binding Protein 2 in the Forebrain is Sufficient to Mediate Behavioral Aspects of Rett Syndrome in Mice , 2006, Biological Psychiatry.

[108]  S. Nelson,et al.  The Disease Progression of Mecp2 Mutant Mice Is Affected by the Level of BDNF Expression , 2006, Neuron.

[109]  H. Beck,et al.  Impaired synaptic plasticity in a rat model of tuberous sclerosis , 2006, The European journal of neuroscience.

[110]  James H. Eubanks,et al.  Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome , 2006, Neurobiology of Disease.

[111]  H. Zoghbi,et al.  Learning and Memory and Synaptic Plasticity Are Impaired in a Mouse Model of Rett Syndrome , 2006, The Journal of Neuroscience.

[112]  J. Gécz,et al.  Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. , 2005, American journal of human genetics.

[113]  B. Hagberg Rett Syndrome: Long-Term Clinical Follow-Up Experiences Over Four Decades , 2005, Journal of child neurology.

[114]  Rudolf Jaenisch,et al.  Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[115]  A. Bird,et al.  Up-regulation of glucocorticoid-regulated genes in a mouse model of Rett syndrome. , 2005, Human molecular genetics.

[116]  C. B. Smith,et al.  Postadolescent Changes in Regional Cerebral Protein Synthesis: An In Vivo Study in the Fmr1 Null Mouse , 2005, The Journal of Neuroscience.

[117]  Lu Chen,et al.  Postsynaptic assembly induced by neurexin-neuroligin interaction and neurotransmitter , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[118]  P. Worley,et al.  Shank Expression Is Sufficient to Induce Functional Dendritic Spine Synapses in Aspiny Neurons , 2005, The Journal of Neuroscience.

[119]  Johan T den Dunnen,et al.  Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. , 2005, American journal of human genetics.

[120]  G. Edelman,et al.  The fragile X mental retardation protein and group I metabotropic glutamate receptors regulate levels of mRNA granules in brain. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[121]  K. Hameister,et al.  Submicroscopic duplication in Xq28 causes increased expression of the MECP2 gene in a boy with severe mental retardation and features of Rett syndrome , 2005, Journal of Medical Genetics.

[122]  Ann Marie Craig,et al.  Neurexins Induce Differentiation of GABA and Glutamate Postsynaptic Specializations via Neuroligins , 2004, Cell.

[123]  Noriyuki Kishi,et al.  MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions , 2004, Molecular and Cellular Neuroscience.

[124]  H. Zoghbi,et al.  Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. , 2004, Human molecular genetics.

[125]  Mark F Bear,et al.  The mGluR theory of fragile X mental retardation , 2004, Trends in Neurosciences.

[126]  Albert David,et al.  X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. , 2004, American journal of human genetics.

[127]  Eric C. Griffith,et al.  Derepression of BDNF Transcription Involves Calcium-Dependent Phosphorylation of MeCP2 , 2003, Science.

[128]  Daisuke Hattori,et al.  DNA Methylation-Related Chromatin Remodeling in Activity-Dependent Bdnf Gene Regulation , 2003, Science.

[129]  H. McDermid,et al.  Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms , 2003, Journal of medical genetics.

[130]  T. Südhof,et al.  α-Neurexins couple Ca2+ channels to synaptic vesicle exocytosis , 2003, Nature.

[131]  Thomas Bourgeron,et al.  Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism , 2003, Nature Genetics.

[132]  R. Jaenisch,et al.  Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[133]  R. Tuchman,et al.  Epilepsy in autism , 2002, The Lancet Neurology.

[134]  Juan I. Young,et al.  Mice with Truncated MeCP2 Recapitulate Many Rett Syndrome Features and Display Hyperacetylation of Histone H3 , 2002, Neuron.

[135]  T. Südhof,et al.  Structure and evolution of neurexin genes: insight into the mechanism of alternative splicing. , 2002, Genomics.

[136]  E. Blennow,et al.  FISH-mapping of a 100-kb terminal 22q13 deletion , 2002, Human Genetics.

[137]  S. Klauck,et al.  A mutation hot spot for nonspecific X-linked mental retardation in the MECP2 gene causes the PPM-X syndrome. , 2002, American journal of human genetics.

[138]  H. Zoghbi,et al.  Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. , 2002, Human molecular genetics.

[139]  D. Cohen,et al.  MECP2 mutation in a boy with language disorder and schizophrenia. , 2002, The American journal of psychiatry.

[140]  J. LaSalle,et al.  Elevated methyl-CpG-binding protein 2 expression is acquired during postnatal human brain development and is correlated with alternative polyadenylation , 2002, Journal of Molecular Medicine.

[141]  Stephen T Warren,et al.  A decade of molecular studies of fragile X syndrome. , 2002, Annual review of neuroscience.

[142]  A. Renieri,et al.  Preserved speech variants of the Rett syndrome: molecular and clinical analysis. , 2001, American journal of medical genetics.

[143]  R. Borgatti,et al.  Disruption of the ProSAP2 gene in a t(12;22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome. , 2001, American journal of human genetics.

[144]  Guosong Liu,et al.  Regulation of Dendritic Spine Morphology and Synaptic Function by Shank and Homer , 2001, Neuron.

[145]  I. Weiler,et al.  Synaptic regulation of protein synthesis and the fragile X protein , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[146]  H. McDermid,et al.  22q13 deletion syndrome. , 2001, American journal of medical genetics.

[147]  R. Jaenisch,et al.  Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice , 2001, Nature Genetics.

[148]  A. Bird,et al.  A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome , 2001, Nature Genetics.

[149]  W. Greenough,et al.  Dendritic spine structural anomalies in fragile-X mental retardation syndrome. , 2000, Cerebral cortex.

[150]  R. Fetter,et al.  Neuroligin Expressed in Nonneuronal Cells Triggers Presynaptic Development in Contacting Axons , 2000, Cell.

[151]  D. Richter,et al.  Somatostatin Receptor Interacting Protein Defines a Novel Family of Multidomain Proteins Present in Human and Rodent Brain* , 1999, The Journal of Biological Chemistry.

[152]  Eunjoon Kim,et al.  Characterization of the Shank Family of Synaptic Proteins , 1999, The Journal of Biological Chemistry.

[153]  H. Zoghbi,et al.  Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2 , 1999, Nature Genetics.

[154]  Y. Hata,et al.  Synamon, a Novel Neuronal Protein Interacting with Synapse-associated Protein 90/Postsynaptic Density-95-associated Protein* , 1999, The Journal of Biological Chemistry.

[155]  T. Boeckers,et al.  Proline-Rich Synapse-Associated Protein-1/Cortactin Binding Protein 1 (ProSAP1/CortBP1) Is a PDZ-Domain Protein Highly Enriched in the Postsynaptic Density , 1999, The Journal of Neuroscience.

[156]  P. Worley,et al.  Coupling of mGluR/Homer and PSD-95 Complexes by the Shank Family of Postsynaptic Density Proteins , 1999, Neuron.

[157]  P. Worley,et al.  Shank, a Novel Family of Postsynaptic Density Proteins that Binds to the NMDA Receptor/PSD-95/GKAP Complex and Cortactin , 1999, Neuron.

[158]  W. Brown,et al.  Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study--preliminary data. , 1999, American journal of medical genetics.

[159]  D. J. Driscoll,et al.  Molecular mechanism of angelman syndrome in two large families involves an imprinting mutation. , 1999, American journal of human genetics.

[160]  D. Linden,et al.  Homer Binds a Novel Proline-Rich Motif and Links Group 1 Metabotropic Glutamate Receptors with IP3 Receptors , 1998, Neuron.

[161]  S. Weed,et al.  Identification of a Novel Cortactin SH3 Domain-Binding Protein and Its Localization to Growth Cones of Cultured Neurons , 1998, Molecular and Cellular Biology.

[162]  A. Bird,et al.  Identification and Characterization of a Family of Mammalian Methyl-CpG Binding Proteins , 1998, Molecular and Cellular Biology.

[163]  J. Strouboulis,et al.  Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription , 1998, Nature Genetics.

[164]  Colin A. Johnson,et al.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex , 1998, Nature.

[165]  Stephen J. Guter,et al.  Linkage-disequilibrium mapping of autistic disorder, with 15q11-13 markers. , 1998, American journal of human genetics.

[166]  T. Südhof,et al.  Neurexins: three genes and 1001 products. , 1998, Trends in genetics : TIG.

[167]  T. Südhof,et al.  Binding of neuroligins to PSD-95. , 1997, Science.

[168]  I. Weiler,et al.  Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[169]  M. Lalande,et al.  UBE3A/E6-AP mutations cause Angelman syndrome , 1996, Nature Genetics.

[170]  Ping Fang,et al.  De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome , 1997, Nature Genetics.

[171]  T. Südhof,et al.  CASK: a novel dlg/PSD95 homolog with an N-terminal calmodulin-dependent protein kinase domain identified by interaction with neurexins , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[172]  T. Südhof,et al.  Structures, Alternative Splicing, and Neurexin Binding of Multiple Neuroligins (*) , 1996, The Journal of Biological Chemistry.

[173]  Raoul C. M. Hennekam,et al.  Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP , 1995, Nature.

[174]  T. Südhof,et al.  Neuroligin 1: A splice site-specific ligand for β-neurexins , 1995, Cell.

[175]  B. Hagberg Clinical Delineation of Rett Syndrome Variants , 1995, Neuropediatrics.

[176]  D. Kwiatkowski,et al.  Tuberous sclerosis. , 1994, Archives of dermatology.

[177]  J. Clayton-Smith,et al.  Clinical research on Angelman syndrome in the United Kingdom: observations on 82 affected individuals. , 1993, American journal of medical genetics.

[178]  A. Bird,et al.  Purification, sequence, and cellular localization of a novel chromosomal protein that binds to Methylated DNA , 1992, Cell.

[179]  J. Sutcliffe,et al.  Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox , 1991, Cell.

[180]  J. Sutcliffe,et al.  Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome , 1991, Cell.

[181]  J. Knoll,et al.  Genetic imprinting suggested by maternal heterodisomy in non-deletion Prader-Willi syndrome , 1989, Nature.

[182]  M. Bear,et al.  Visual experience regulates gene expression in the developing striate cortex. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[183]  D. Ledbetter,et al.  Uniparental disomy as a mechanism for human genetic disease. , 1988, American journal of human genetics.

[184]  D. Ledbetter,et al.  Is Angelman syndrome an alternate result of del(15)(q11q13)? , 1987, American journal of medical genetics.

[185]  W. Travis,et al.  A Report of Three Cases , 1986 .

[186]  J. Opitz,et al.  Consideration of connective tissue dysfunction in the fragile X syndrome. , 1984, American journal of medical genetics.

[187]  Jean Aicardi,et al.  A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: Report of 35 cases , 1983, Annals of neurology.

[188]  C. Harrison,et al.  The fragile X: a scanning electron microscope study. , 1983, Journal of medical genetics.

[189]  C. F. von Reyn,et al.  Infection of an infant with an adult Toxocara cati (Nematoda). , 1978, The Journal of pediatrics.

[190]  S. Pelc,et al.  [Happy-puppet syndrome]. , 1976, Helvetica paediatrica acta.

[191]  H. Lubs A marker X chromosome. , 1969, American journal of human genetics.

[192]  A Rett,et al.  [On a unusual brain atrophy syndrome in hyperammonemia in childhood]. , 1966, Wiener medizinische Wochenschrift.

[193]  Harry Angelman,et al.  ‘Puppet’ Children A Report on Three Cases , 1965 .

[194]  J. Bell,et al.  A PEDIGREE OF MENTAL DEFECT SHOWING SEX-LINKAGE , 1943, Journal of neurology and psychiatry.

[195]  D. M. Bourneville Sclerose tubereuse des circonvolutions cerebrales : idiotie et epilepsie hemiplegique , 1880 .